Glaxosmithkline (GSK)

 

GSK Share PerformanceMore

52 week high1,745.5 11/10/16
52 week low1,277.5 14/12/15
52 week change 164.0 (12.48%)
4 week volume198,944,340 13/11/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

November's 10 most-bought trusts

Woodford Patient Capital saw its popularity wane in November, slipping into fourth place. David Brenchley looks at whet...

Director Deals - GlaxoSmithKline PLC (GSK)

Simon Dingemans, Financial Director, exercised 216 shares in the company on the 1st December 2016 at a price of 1247.00p. ...

Director/PDMR Shareholding

RNS Number: 8685Q GlaxoSmithKline PLC 02 December 2016 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr S Dingemans b) Position/status Chief Financial Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market partic...

GSK files closed triple therapy for COPD in EU

GlaxoSmithKline and Innoviva have announced the filing by GSK of a regulatory submission with the European Medicin...

GSK files closed triple therapy for COPD in EU

RNS Number: 8557Q GlaxoSmithKline PLC 02 December 2016 Issued: Friday, 2 December 2016, London UK - LSE Announcement GSK files EU regulatory submission for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by G...

GSK confirms Japan approval for Relvar Ellipta

GlaxoSmithKline and Innoviva, have announced that the Japanese Ministry of Health, Labour and Welfare has approved ...

Relvar Ellipta approved in Japan for COPD

RNS Number: 7952Q GlaxoSmithKline PLC 02 December 2016 Issued: Friday 2 December 2016, London UK Relvar Ellipta 100/25 mcg gains approval in Japan for use in patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved...

Total Voting Rights

RNS Number: 7064Q GlaxoSmithKline PLC 01 December 2016 GlaxoSmithKline plc Total Voting Rights and Capital In conformity with Disclosure and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following: The Company's issued share capital as at 30 November 2016 consisted of 5,367,734,859 ordinary shares of 25 p...

Fundamental DataMore

P/E ratio8.48
EPS174.3
Dividend yield5.413 %

Latest discussion posts More

  • broker view

    update from beaufort: https://www.research-tree.com/research/breakfast-today/e68cf8b2-1e9e-49a6-9007-45bbab47c279
    5-Dec-2016
    Sambram
  • Re: Added

    Added at the open and yesterday, now above my intended holding %, however longer term this is beginning to look compelling. Good to see the Japan news, my better half ...
    2-Dec-2016
    EssentialInvestor
  • Japan approves Relvar

    This is the second significant announcement from GSK in a ...
    2-Dec-2016
    gamesinvestor

Users' HoldingsMore

Users who hold Glaxosmithkline also hold..
VODAFONE GRP.35%
BP34%
NATIONAL GRID32%
RDS 'B'31%
LLOYDS GRP.29%

Codes & Symbols

ISINGB0009252882
SymbolsGSK, LSE:GSK, GSK.L, GSK:LN, LON:GSK, XLON:GSK